Open Access. Powered by Scholars. Published by Universities.®
- Discipline
- Keyword
-
- Lymphoma (2)
- Angiogenesis Inhibitors (1)
- Brain Neoplasms (1)
- Carcinoma (1)
- Fertility Preservation (1)
-
- Glial tumor (1)
- Glioblastomas drug therapy (1)
- Gonadotropin Releasing Hormone agonists (1)
- HLA; HLA-Bw4; KIR; KIR-ligand; MHC class I; cancer immunotherapy; natural killer cells (1)
- Hepacivirus (1)
- Hepatitis C (1)
- Hepatocellular (1)
- Heterografts (1)
- Immune response (1)
- Liver Neoplasms (1)
- Malignant melanoma (1)
- Myocardial Infarction (1)
- Neoplasms (1)
- Neoplasms etiology (1)
- Non-Hodgkin (1)
- Olig-2 (1)
- Percutaneous Coronary Intervention (1)
- Prognosis (1)
- RMDO-2 (1)
- Risk Factors (1)
- ST Elevation Myocardial Infarction (1)
- Synaptophysin expression (1)
- T lymphocytes (1)
- Tumor-immune dynamics (1)
Articles 1 - 7 of 7
Full-Text Articles in Oncology
Temporal Trends And Outcomes Of Acute Myocardial Infarction In Patients With Cancer, N Pothineni, N Shah, Yogita Rochlani, M Saad, S Kovelamudi, K Marmagkiolis, S Bhatti, M Cilingiroglu, Wilbert Aronow, A Hakeem
Temporal Trends And Outcomes Of Acute Myocardial Infarction In Patients With Cancer, N Pothineni, N Shah, Yogita Rochlani, M Saad, S Kovelamudi, K Marmagkiolis, S Bhatti, M Cilingiroglu, Wilbert Aronow, A Hakeem
NYMC Faculty Publications
Background: Data on outcomes of ST-elevation myocardial infarction (STEMI) in patients with cancer are scarce. We investigated the nationwide trends in admissions for STEMI, utilization of percutaneous coronary intervention (PCI), and in-hospital outcomes in patients with the three most common cancer diagnoses (lung, breast, and colon) compared to patients without cancer. Methods: We conducted an administrative database study using the Nationwide Inpatient Sample (NIS). All in-patient hospitalizations for STEMI from 2001 to 2011 were identified. Patients with concomitant diagnosis of lung, breast or colon cancer were identified using appropriate International classification of diagnosis (ICD 9-CM) codes. Primary outcome was utilization …
Hepatitis C Virus And Nonliver Solid Cancers: Is There An Association Between Hcv And Cancers Of The Pancreas, Thyroid, Kidney, Oral Cavity, Breast, Lung, And Gastrointestinal Tract?, S Qadwai, T Rehman, Jonathan Barsa, Z Solangi, Edward Lebovics
Hepatitis C Virus And Nonliver Solid Cancers: Is There An Association Between Hcv And Cancers Of The Pancreas, Thyroid, Kidney, Oral Cavity, Breast, Lung, And Gastrointestinal Tract?, S Qadwai, T Rehman, Jonathan Barsa, Z Solangi, Edward Lebovics
NYMC Faculty Publications
Hepatitis C virus (HCV) is known for its oncogenic potential and has been found to be associated with hepatocellular carcinoma (HCC) and non-Hodgkin lymphoma. It has also been postulated that HCV may play a role in the development of other extrahepatic solid tumors of other organs of the body since it has been isolated from the vessel wall, kidney, and oral mucosa. In this article, we have reviewed epidemiological studies that have been done to look into the relationship of HCV with nonliver solid cancers of the pancreas, thyroid, renal, oral cavity, breast, and lung and nonpancreatic gastrointestinal cancers. Based …
Rmdo-2, Olig-2 And Synaptophysin Expression Is A Frequent Event In Malignant Melanoma: Diagnostic Pitfalls In Glial Tumor, Taliya Farooq, Esther C. Yoon, Anas Mashlah, Sina Zomorrodian, George Kleinman
Rmdo-2, Olig-2 And Synaptophysin Expression Is A Frequent Event In Malignant Melanoma: Diagnostic Pitfalls In Glial Tumor, Taliya Farooq, Esther C. Yoon, Anas Mashlah, Sina Zomorrodian, George Kleinman
NYMC Faculty Posters
No abstract provided.
Reply To M. Lambertini Et Al, Kutluk Oktay, V Turan, G Bedoschi
Reply To M. Lambertini Et Al, Kutluk Oktay, V Turan, G Bedoschi
NYMC Faculty Publications
No abstract provided.
A Mathematical Investigation On Tumor-Immune Dynamics: The Impact Of Vaccines On The Immune Response, Jonathan Quinonez, Neethi Dasu, Mahboob Qureshi
A Mathematical Investigation On Tumor-Immune Dynamics: The Impact Of Vaccines On The Immune Response, Jonathan Quinonez, Neethi Dasu, Mahboob Qureshi
College of Osteopathic Medicine (TUN) Publications and Research
Mathematical models analyzing tumor-immune interactions provide a framework by which to address specific scenarios in regard to tumor-immune dynamics. Important aspects of tumor-immune surveillance to consider is the elimination of tumor cells from a host’s cell-mediated immunity as well as the implications of vaccines derived from synthetic antigen. In present studies, our mathematical model examined the role of synthetic antigen to the strength of the immune system. The constructed model takes into account accepted knowledge of immune function as well as prior work done by de Pillis et al. All equations describing tumor-immune growth, antigen presentation, immune response, and interaction …
Hla-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared To Hla-Bw4-T-80 And Hla-A-Bw4 Isoforms In Rituximab Or Dinutuximab-Based Cancer Immunotherapy, Amy Erbe, Wei Wang, Patrick Reville, Lakeesha Carmichael, Kyungmann Kim, Mehmet F. Ozkaynak, Paul Sondel
Hla-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared To Hla-Bw4-T-80 And Hla-A-Bw4 Isoforms In Rituximab Or Dinutuximab-Based Cancer Immunotherapy, Amy Erbe, Wei Wang, Patrick Reville, Lakeesha Carmichael, Kyungmann Kim, Mehmet F. Ozkaynak, Paul Sondel
NYMC Faculty Publications
Killer-cell immunoglobulin-like receptors (KIRs) are a family of glycoproteins expressed primarily on natural killer cells that can regulate their function. Inhibitory KIRs recognize MHC class I molecules (KIR-ligands) as ligands. We have reported associations of KIRs and KIR-ligands for patients in two monoclonal antibody (mAb)-based trials: (1) A Children's Oncology Group (COG) trial for children with high-risk neuroblastoma randomized to immunotherapy treatment with dinutuximab (anti-GD2 mAb) + GM-CSF + IL-2 + isotretinion or to treatment with isotretinoin alone and (2) An Eastern Cooperative Oncology Group (ECOG) trial for adults with low-tumor burden follicular lymphoma responding to an induction course of …
Intravenous Formulation Of Het0016 Decreased Human Glioblastoma Growth And Iimplicated Survival Benefit In Rat Xenograft Models, M Jain, N Gamage, M Alsulami, A Shankar, B Achyut, Austin Guo, A Arbab, A Arbab
Intravenous Formulation Of Het0016 Decreased Human Glioblastoma Growth And Iimplicated Survival Benefit In Rat Xenograft Models, M Jain, N Gamage, M Alsulami, A Shankar, B Achyut, Austin Guo, A Arbab, A Arbab
NYMC Faculty Publications
Glioblastoma (GBM) is a hypervascular primary brain tumor with poor prognosis. HET0016 is a selective CYP450 inhibitor, which has been shown to inhibit angiogenesis and tumor growth. Therefore, to explore novel treatments, we have generated an improved intravenous (IV) formulation of HET0016 with HPssCD and tested in animal models of human and syngeneic GBM. Administration of a single IV dose resulted in 7-fold higher levels of HET0016 in plasma and 3.6-fold higher levels in tumor at 60 min than that in IP route. IV treatment with HPssCD-HET0016 decreased tumor growth, and altered vascular kinetics in early and late treatment groups …